UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2008
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Florida
|
|
000-27836
|
|
65-0643773 |
|
|
|
|
|
|
| (State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 20100
(Address of principal executive offices) (Zip Code)
(Former Name or Former Address, if Changed Since Last Report)
Registrant’s telephone number, including area code: +972-4-988-9488
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01. Other Events
On December 19, 2008, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing the enrollment of the first patient in a worldwide, multi-center, open-label, switchover
trial to assess the safety and efficacy of prGCD. prGCD is the Company’s proprietary plant cell
expressed recombinant form of human glucocerebrosidase (GCD) that is in development for the
treatment of Gaucher disease, a rare and serious lysosomal storage disorder in humans. prGCD is
also currently being evaluated in a pivotal phase III, multi-center, randomized, double-blind,
parallel group, dose-ranging trial to assess the safety and efficacy of prGCD in naive patients
suffering from Gaucher disease. The Company recently announced that it had completed patient
enrollment in the phase III clinical trial. A copy of the press release is attached hereto as
Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated December 19, 2008.
2